CAS: 1020210-12-1

Meayamycin B is a synthetic macrolide, a complex organic compound, which is derived from the natural product FR901464. This compound functions as an antagonist of the spliceosome, the cellular machinery responsible for pre-mRNA splicing. By binding to specific components of the spliceosome, Meayamycin B disrupts the splicing process, leading to the accumulation of unspliced precursor mRNA. This action effectively induces apoptosis in cancer cells, making it a notable candidate for cancer therapy research. The use of Meayamycin B is predominantly seen in molecular biology and cancer research settings. Its ability to precisely target and disrupt gene expression pathways provides researchers with a valuable tool to study RNA processing in cells. Additionally, due to its pro-apoptotic effect on cancerous cells, it is explored for therapeutic developments in oncology. The unique mechanism of action of Meayamycin B offers insights into spliceosomal functions and potential interventions in diseases characterized by aberrant RNA splicing.